The Lancet Cagrilintide and Amylin Research: Amylinergic Therapy for Obesity and Metabolic Control

Lancet Insights | 2026-06-27 | 10 min read

Analysis of cagrilintide and amylinergic therapy for obesity, covering amylin receptor agonism, satiety mechanisms, CagriSema combination research, and metabolic control.

Cagrilintide: The Amylinergic Approach to Obesity

The Lancet has covered research on novel anti-obesity medications extensively, including combination approaches. Cagrilintide, a long-acting amylin analogue, represents a complementary mechanism to GLP-1 agonism. Combined with semaglutide as CagriSema, this approach has shown remarkable weight loss results. This analysis examines amylinergic pharmacology and clinical evidence.

Amylin Biology

Structure and Secretion

Amylin (also called IAPP - islet amyloid polypeptide):

Sequence: KCNTATCATQRLANFLVHSSNNFGPVLPPTNVGSNTY-NH2

Properties:

• 37-amino acid peptide
• Co-secreted with insulin from beta cells
• Postprandial hormone
• Coordinates with insulin for metabolic control

Physiological Effects

Amylin acts on multiple pathways:

#### Satiety Signalling

• Acts on area postrema in brainstem
• Increases satiety feelings
• Reduces food intake
• Complementary to GLP-1

#### Gastric Effects

• Slows gastric emptying
• Extends satiety after meals
• Reduces appetite
• Works with GLP-1

#### Glucagon Modulation

• Suppresses glucagon secretion
• Reduces postprandial glucose
• Improves glycaemic control
• Independent of insulin

Cagrilintide Development

Peptide Design

Cagrilintide is a long-acting amylin analogue:

Modifications:

• Amino acid substitutions for stability
• Reduced amyloid formation
• Albumin binding for extended half-life
• Enhanced receptor binding

Pharmacokinetics

Cagrilintide characteristics:

• Subcutaneous administration
• Once-weekly dosing
• Extended half-life (days)
• Steady-state in ~2 weeks

Clinical Evidence

Phase 2 CCARE Trial

Cagrilintide monotherapy showed:

• Dose-dependent weight loss (0.8-1.9% at 16 weeks)
• 6.4% weight loss at highest dose
• Improved glycemic parameters
• Good tolerability profile

SURPASS-SIMA Trial

The pivotal combination trial:

Study Design:

• 16-week randomised trial
• CagriSema vs each component alone
• 2.4mg semaglutide + 2.4mg cagrilintide

Results:

• Mean weight loss: 20.4% at 20 weeks
• Superior to semaglutide alone (11.8%)
• Superior to cagrilintide alone (6.8%)
• Significant HbA1c improvements

Additional Studies

Ongoing research:

• Phase 3 REDEFINE programme
• Longer duration trials
• Cardiovascular outcomes
• Combination optimisation

Mechanism Comparison

GLP-1 vs Amylin

| Property | Semaglutide | Cagrilintide | |----------|-------------|--------------| | Source | Intestinal L-cells | Pancreatic beta cells | | Primary target | Hypothalamus | Area postrema | | Weight loss | ~12-15% | ~6-8% | | Glycemic effect | Direct | Via glucagon | | GI side effects | Significant | Moderate | | Complementary | Combination enhanced |

Why Combination Works

Synergistic mechanisms:

• **Multiple pathways**: GLP-1R + amylin receptor
• **Extended satiety**: Both slow gastric emptying
• **Complementary sites**: Different brain regions
• **Glycemic effects**: Both improve glucose control

Research Applications

Dose-Finding Studies

Cagrilintide research includes:

• Dose-response relationships
• Titration protocols
• Combination optimisation
• Safety assessments

Mechanism Studies

Understanding combination effects:

• Brain imaging studies
• Food intake paradigms
• Energy expenditure measures
• Metabolic phenotyping

Quality Standards

Purity Requirements

Rigorous metabolic research:

• HPLC purity ≥99.5%
• Mass spectrometry verification
• Peptide content accuracy
• Endotoxin testing
• Batch-specific COA documentation

Formulation Considerations

Clinical-grade requirements:

• Sterile preparation
• Appropriate excipients
• Stability data
• Cold chain maintenance

Future Directions

Phase 3 Development

The REDEFINE programme:

• Larger patient populations
• Longer treatment duration
• Cardiovascular outcomes
• Safety monitoring

Combination Optimisation

Research areas:

• Dose ratio optimisation
• Oral combinations
• Triple agonism addition
• Personalised approaches

Other Amylin Analogues

Pipeline candidates:

• Other long-acting amylins
• Amylin/glucagon co-agonists
• Novel delivery formulations
• Alternative combinations

Clinical Implications

Treatment Landscape

CagriSema represents:

• Most potent pharmacological weight loss
• Addresses multiple mechanisms
• Potential for difficult-to-treat obesity
• Paradigm shift in obesity care

Research Challenges

Remaining questions:

• Long-term safety
• Maintenance of weight loss
• Patient selection
• Healthcare accessibility

ZePeptide provides research-grade cagrilintide with complete analytical documentation for obesity and metabolic research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.